· AIM:Toevaluatethelong-termefficacyandsafetyof dexamethasoneimplantsinsubjectsaffectedbydiabetic macular edema (DME) resistant to anti-vascular endothelialgrowthfactor(VEGF)therapy.
· METHODS:Thirty-twoDMEpatientswereenrolled.A 700microgramslowreleaseIntravitrealDexamethasone Implant(Ozurdex誖 )wasplacedinthevitreouscavity.All patientswerefollowedfor18mo.Best-correctedvisual acuity (BCVA)measuredwithEarlyTreatmentDiabetic Retinopathy Study (ETDRS) and central macular thickness(CMT)examswerecarriedoutatbaseline(T0) andafter1(T1),3(T3),4(T4),6(T6),9(T9),12(T12),15 (T15),and18mo(T18)postinjection.
· RESULTS:RepeatedmeasuresANOVAshowedan effectoftreatmentonETDRS ( <0.0001).Posthoc analysesrevealedthatETDRSvaluesweresignificantly increasedatT1,T3,T4,T9,andT15 ( <0.001)as comparedtobaselinevalue (T0).AtT6,T12,andT18, ETDRSvalueswerestillstatisticallyhigherthanbaseline ( <0.001 T0).However,atthesetimepoints,we observedatrendtoreturn tobaselineconditions. ANOVAalsoshowedaneffectoftreatment ( <0.0001). CMTdecreasedsignificantlyatT1,T3,T4,T9,andT15 ( <0.001).AtT6( <0.01),T12andT18( <0.001)CMT wasalsosignificantlylowerthanT0althoughatrendto returntothebaselineconditionswasalsoobserved. [1] .DMErepresentsthe firstchangeoccurringintheretina,leadingtoreducedvisual acuityandbreakdownoftheblood-retinalbarrier [2] .Increased glucose levels caninducenumerousbiochemicaland metabolicchangescontributingtoendothelialdysfunction, inflammatoryprocessesandincreasedtrans-vascularpassage ofmacromolecules [3] [4] .Allthesefactorscontributeto disruptionoftheblood-retinalbarrier,accumulationoffree radicals,activationofvascularendothelialgrowthfactor (VEGF)pathwayin endothelialintercellular junctions, pericyteloss,andretinalvesselleukostasis [5] [6] [7] . Todate,thegoalsoflocaleyetreatmentarethediminutionof macularedema,tostopthediseaseprogressionand,possibly, toimprovethevision.Intravitrealinjectionsofanti-VEGF agentsisthecurrenttreatmentofchoiceinDME [7] [8] .Other therapeuticoptionsarevitrectomy,proteinkinaseC(PKC) inhibitorsandsteroids [7, [9] [10] [11] . Dexamethasoneisoneofthemostpotentglucocorticoid availableinophthalmology [12] .Itexertsanti-inflammatory, anti-angiogenic,anti-edematousandanti-proliferativeeffects byinfluencingseveralsignaltransductionpathways [13] . Dexamethasonestabilizestheblood-retinalbarrier modulationofproteinsinvolvedinVEGFreceptor downstreampathway [14] .Previousstudy [15] hasshownthat intravitrealinjectionofdexamethasoneimprovesDMEby inhibiting leukostasisand decreasingsynthesisand expressionofintracellularadhesionmolecule-1(ICAM-1). Moreover,ithasbeenshownthatactivationofglucocorticoid receptormayprotecttheretinalphotoreceptorsthroughan anti-apoptoticaction [16] . Thedexamethasoneimplant(Ozurdex,AllerganInc.,Irvine, CA,USA)isanewtherapeuticapproachapprovedinItaly fortheintravitrealtreatmentofmacularedemaaftervascular retinalocclusions [17] .Duetoitsprogressivelybiodegradable formoflacticandglycolicacidcopolymers,itisfoundin goodconcentrationsinthevitreouschamberforaperiodof upto180dafterasingleinjection [18] [19] . OnestudyhasshownthatIntravitrealDexamethasone Implantisefficientinpatientswithrecalcitrantmacular edemasecondarytoretinalveinocclusion [20] .Inaddition,data onthelongtermefficacyandsafetyofdexamethasone implantinDMEhavebeenprovidedinthestudyofHaller [21] and,morerecently,inthatofMastropasqua [22] . Inordertoconfirmthesedataandprovidefurtherevidence fortheuseofdexamethasoneinDME,inthisstudywe evaluatedtheefficacyandsafetyofdexamethasoneimplant injectionsinpatientsaffectedbyDMEresistanttoanti-VEGF therapy(loadingphase),asascertainedbyopticalcoherence tomography(OCT)showingnosignsofimprovementsin centralmacularthickness(CMT)andbest-correctedvisual acuity(BCVA). followup,thesepatientsshowedanuclearcataractgrade1 andcorticalgrade1.
SUBJECTSANDMETHODS

Optical Coherence Tomography Evaluation
The evaluation oftheintegrityofELMandEZofthe photoreceptorinterface,carriedoutatbaseline,6,12and 18mo,didnotrevealalterationsduetothedexamethasone implant. DISCUSSION Thisstudywasperformedtoinvestigatetheefficacyand safetyofIntravitrealDexamethasoneImplant(Ozurdex ® ) overtimeinpatientsaffectedbypersistentDME. Theresults,aspreviouslyreported [24] ,showedthatIntravitreal DexamethasoneImplantinducedanimprovementinBCVA, andCMTvalueswithaneffectlasting6mo.Inaddition,we foundthatBCVAandCMTvaluesdidnotreturntothe baselineconditionsduring18mofollow-up. ThisstudyindicatesthattheIntravitrealDexamethasone Implantisbothefficientandsafenotonlyforthetreatmentof secondarymacularedemaproducedbybranchretinal veinocclusion(BRVO)andcentralretinalveinocclusion (CRVO) [19] [20] ,butalsoforsecondarymacularedemaafter diabeticretinopathy [22] .InpatientswithpersistentDME, importantfunctional (BCVA)andmorphologic(CMT) improvementoftheretinainthetreatedeyewereobserved. Our datasuggest thatthe maximumeffectsofthe dexamethasoneimplantoccurat3moandslowlydecrease frommonth4to6.Thisfindingisinlinewithprevious studiesshowingthattheimprovementofvisualparameters alreadystartsfromdaythreeoftheintravitrealimplantand decreasesovertime [25] [26] [27] [28] .Ourresultsalsoshowedasimilar clinicalcourseafterthesecondandthethirddexamethasone reinjection,althoughattheendofthefollow-uptheBCVA andCMTvalueswereimprovedpersistentlywhencompared tothebaselinevalues.Thiscyclictrendmaybeduetoa reducedreleaseofthedrugovertime.Thus,onecan hypothesizethatthegradualdecreaseoftheefficacymaybe duetoreducedconcentrationsofdexamethasoneinthe vitreous.Alternatively,itispossiblethatthechronicnatureof thisillnessmaylimittheefficacyoftheimplantovertime. Otherstudiesarenecessarytoelucidatethismechanisms [29] . Nonetheless,despitethiseffect,ourdatasupportthenotion thatintravitrealcorticosteroidsmayrepresentaneffective treatmentforDME,notonlytopreventvisualloss,butalso torecoverofvisualacuity [18, 30] .Theseagentshave anti-inflammatoryandanti-angiogenicpropertiesstabilizing theinnerblood-retinabarrierandactonallinflammatory mediators.Corticosteroids modulatetheireffectsby interactingwithspecificnuclearsteroid-hormone-receptors. Thesereceptorsmainlyresideinthecytoplasminaninactive formuntilsteroidbinding,receptoractivationand translocationtothenucleus [31] .Althoughcorticosteroids predominantlyactbyincreasinggenetranscription,thereare well-documentedexamplesshowingthatglucocorticoids decreasegenetranscription [7] .Previousstudy [6] hasshownthat intravitrealinjectionofdexamethasoneimprovesDMEby inhibitingleukostasisanddecreasingsynthesisand expressionofICAM-1.Inaddition,corticosteroidsmay exertsomeoftheirimmediateeffectsbynon-genomic mechanisms [32] .Moreover,ithasbeenshownthatactivation ofglucocorticoidreceptorprotectstheretinalphotoreceptors andhasanti-apoptoticaction [33] . ThegreaterefficacyofdexamethasoneinDMEpatients resistanttoanti-VEGFtherapymaybeduetothe characteristicoftheimplantthat,unlikeanti-VEGFs,allows astablereleaseof0.7mgofpreservative-freedexamethasone intothevitrealchamber [19, 21, 25, 27] .Theadministrationrouteis essentialforthetherapeuticefficacyofsteroids.Infact,oral steroidadministrationmaycausesystemicsideeffectsand, aboveall,theconcentrationofsteroidinthevitreousisvery low [14] .Instead,theuseofdrugsadministereddirectlyintothe vitreousallowsachievingappropriateconcentrationatthe siteofdisease,withminorsystemicsideeffects [5, 34] . Interestinglyweobservedthatrepeatedinjectionsof dexamethasonedidnotinduceserioussideeffects,afinding inlinewithotherstudies [17, 19, 22, [27] [28] 35] .Noneofourpatientshad uncontrolledhypertension,hyperlipidemia,renaldisease,or othercomorbiditiesduringthefollow-upperiod.Anincrease inIOPthatoccurredin15% ( =5)ofpatientswaseasily handled with anantiglaucomatousmono-therapy. Dexamethasoneimplanthasalsolowerincidenceofcataract andglaucomathanothersteroids [17] . Inconclusion,ourfindingsdemonstratethatIntravitreal DexamethasoneImplant(0.7mg)improvesBCVAandhasa safetyprofileconsistentwithpreviousdata [20, 36] inDME patientsresistanttoanti-VEGFtherapy.Ourdataalsoshow thattheuseofdrugsadministereddirectlyintothevitreous allowsachievingappropriateandlong-lastingconcentration atthesiteofdiseasewithoutsystemicsideeffects,withthe finalaimtoimprovetherapeuticresponseandreducetherate forre-treatment.TheuseofsteroidsinDMEpatients representsanalternativetherapeuticstrategyincaseswhere othertherapies(laseroranti-VEGF)havefailed [24, [37] [38] [39] . Nonetheless,otherstudiesarenecessarytoconfirmthese data.
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